Full Press Release Details
GERMANTOWN, Md. , Dec. 24, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON ), and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the company will host a conference call on Wednesday, December 26 , at 8:30 AM ET to provide business updates, including an overview of Precigen's recent transition from an exclusive channel collaboration model to an agile R&D engine for greater focus, full developmental control and acceleration of its core programs and an overview of the recently announced FDA clearance for the Investigational New Drug (IND) application for the first-in-class PRGN-3006 UltraCAR-T ™ therapy for treatment of patients with relapsed or refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS).
Precigen invites the public and media to listen to the presentation via live audio webcast, which can be accessed under "Investor Relations" in the Events section of the Intrexon website at investors.dna.com/events . Participants may dial in to the conference call at +1-888-317-6003 (Domestic US), +1-866-284-3684 ( Canada ), and +1-412-317-6061 (International) and provide the participant number 6733054 to join the call. A replay of the webcast will be archived on the Intrexon website following the presentation.
Precigen Media Contact: Donelle M. Gregory [email protected]
SOURCE Precigen, Inc.